3.0826
11.31%
0.3426
Leap Therapeutics Inc 주식(LPTX)의 최신 뉴스
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Vera Therapeutics (NASDAQ:VERA) vs. Pivotal Therapeutics (OTCMKTS:PVTTF) Financial Analysis - Defense World
Global Gastric Cancer Diagnostics Market is Expected to Expand at a CAGR of ~7% by 2030 | DelveInsight - PR Newswire UK
Lululemon Athletica (NASDAQ:LULU) Price Target Lowered to $326.00 at Morgan Stanley - Defense World
Farther Finance Advisors LLC Has $1.20 Million Stake in Paychex, Inc. (NASDAQ:PAYX) - Defense World
Laramide Resources Ltd. (TSE:LAM) Director Buys C$10,200.00 in Stock - Defense World
Rothschild Investment LLC Buys Shares of 8,904 Capital Group Growth ETF (NYSEARCA:CGGR) - Defense World
Picton Mahoney Asset Management Takes $71,000 Position in American Woodmark Co. (NASDAQ:AMWD) - Defense World
Rothschild Investment LLC Makes New Investment in iShares Core MSCI Europe ETF (NYSEARCA:IEUR) - Defense World
Farther Finance Advisors LLC Has $1.36 Million Stake in McKesson Co. (NYSE:MCK) - Defense World
Intel Co. (NASDAQ:INTC) Shares Purchased by Farther Finance Advisors LLC - Defense World
Rothschild Investment LLC Takes Position in BlackRock MuniHoldings Quality Fund II, Inc. (NYSE:MUE) - Defense World
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Trims Stock Holdings in Universal Health Services, Inc. (NYSE:UHS) - Defense World
Allspring Global Investments Holdings LLC Sells 103,605 Shares of Wabash National Co. (NYSE:WNC) - Defense World
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update - MarketBeat
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 - GlobeNewswire
Atossa and Quantum Leap dose first subject in breast cancer therapy trial - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - StockTitan
Vanguard Group Inc. Buys 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) - MarketBeat
AstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average of $11,535.34 - Defense World
Vanguard Group Inc. Acquires 156,044 Shares of Priority Technology Holdings, Inc. (NASDAQ:PRTH) - Defense World
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - MarketBeat
Leap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short Interest - Defense World
Analysts Issue Forecasts for Leap Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:LPTX) - MarketBeat
Q3 2024 EPS Estimates for MiNK Therapeutics, Inc. (NASDAQ:INKT) Boosted by Analyst - Defense World
HLS Therapeutics Inc. (TSE:HLS) to Post Q3 2024 Earnings of ($0.19) Per Share, Stifel Canada Forecasts - Defense World
Leap Therapeutics (NASDAQ:LPTX) Given Buy Rating at HC Wainwright - MarketBeat
Leap Therapeutics’ (LPTX) Buy Rating Reaffirmed at HC Wainwright - Defense World
LPTX Stock Earnings: Leap Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Leap Therapeutics Reports Second Quarter 2024 Financial Results - citybiz
Orphan Drugs and Rare Diseases Conference (Boston, MA, United StatesOctober 17-18, 2024)Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision TreatmentsResearchAndMarkets.com - Manchestertimes
Leap Therapeutics Reports Second Quarter 2024 Financial Results - PR Newswire
Venous Leg Ulcers Treatment Industry Size, Innovations Driving Industry Evolution (2024-2035) - அக்னி செய்திகள்
Travere Therapeutics (NASDAQ:TVTX) PT Raised to $14.00 at Barclays - Defense World
Global Venous Leg Ulcers Treatment Market 2024 Analysis by Top Key Players |MediWound Ltd, NovaLead Pharma Pvt Ltd - The NRI News
Tivic Health Systems Inc. (NASDAQ: TIVC): A Promising Leap with New Patents and Market Performance - BP Journal
Acadian Asset Management LLC Has $750,000 Stock Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World
Leap and Samsung SmartThings Deploy Automated Virtual Power Plant Solutions - Yahoo Finance
EASA Certifies LEAP-powered Airbus A321XLR - Yahoo Finance
Exploring HER2 Targeting: Transforming Treatment for Metastatic and Locally Advanced HER2+ Cancers - PRIME® Continuing Medical Education
Taking the Leap: Moving From Large to Small Biopharmas - BioSpace
Leap Health Announces Partnership with Covet Health to Reduce Specialty Drug Costs and Improve Patient Outcomes - Yahoo Finance
LEAP Introduces AI Innovations to Drive the Future of the Legal Profession - Yahoo Finance
Allspring Global Investments Holdings LLC Invests $34,000 in Advance Auto Parts, Inc. (NYSE:AAP) - Defense World
Short Interest in Leap Therapeutics, Inc. (NASDAQ:LPTX) Drops By 14.5% - MarketBeat
Short Interest in Mama’s Creations, Inc. (NASDAQ:MAMA) Drops By 14.2% - Defense World
Allspring Global Investments Holdings LLC Acquires New Shares in Hess Midstream LP (NYSE:HESM) - Defense World
Twilio Inc. (NYSE:TWLO) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
Sumitomo Mitsui Trust Holdings Inc. Acquires Shares of 10,370 Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) - Defense World
China Yuchai International (NYSE:CYD) Receives New Coverage from Analysts at StockNews.com - Defense World
Leap Therapeutics, Inc. (LPTX) Reports Q2 Loss - Yahoo Canada Shine On
Kintara Therapeutics restructures share designations By Investing.com - Investing.com India
Leap Therapeutics Shareholders Elect Directors, Approve Proposals By Investing.com - Investing.com
Neovasc Inc (NVCN-Q) QuotePress Release - The Globe and Mail
Leap Therapeutics (NASDAQ:LPTX) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
Nkarta (NASDAQ:NKTX) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Estimate Leap Therapeutics, Inc. (LPTX) to Report a Decline in Earnings: What to Look Out for - Yahoo New Zealand News
Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight - Barchart
Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight - openPR
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study - Yahoo New Zealand News
Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine - BioPharma Dive
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA - Yahoo New Zealand News
Financial Metrics Check: Leap Therapeutics Inc (LPTX)'s Ratios for Trailing Twelve Months – DWinneX - The Dwinnex
Biliary Tract Cancer Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies ... - openPR
자본화:
|
볼륨(24시간):